Early Clinical Experience With Anidulafungin In Patients With Liver Disease In The United Kingdom
25. März 2014 aktualisiert von: Pfizer
A Study To Describe The Early Clinical Experience With Anidulafungin In Patients With Liver Disease At King's College Hospital NHS Trust, London
The purpose of this study is to describe the real world effectiveness of anidulafungin in clinical practice in a large Liver Unit in the United Kingdom.
Studienübersicht
Detaillierte Beschreibung
All subjects that have been treated with Anidulafungin according to its licence during the period of July 2009 and September 2010 will be included.
Studientyp
Beobachtungs
Einschreibung (Tatsächlich)
50
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
-
London, Vereinigtes Königreich, SE5 9RS
- Pfizer Investigational Site
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
18 Jahre bis 90 Jahre (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Nein
Studienberechtigte Geschlechter
Alle
Probenahmeverfahren
Nicht-Wahrscheinlichkeitsprobe
Studienpopulation
Subjects admitted with candidiasis infections to the Liver Unit at King's College Hospital (United Kingdom) who are prescribed anidulafungin.
Beschreibung
Inclusion Criteria:
- Subjects who have been prescribed anidulafungin between 1st July 2009 and 30th September 2010.
Patients admitted to specialist liver unit wards and the Liver Intensive Therapy Unit during this period
Exclusion Criteria:
- Patients who participated in any interventional clinical trial during this episode of sepsis.
Patients who received anidulafungin for infection prophylaxis
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
|---|---|
|
Anidulafungin
|
A single 200 mg loading dose should be administered on Day 1, followed by 100 mg daily thereafter.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of Participants With Favorable Outcome
Zeitfenster: Day 28 post-treatment
|
Favorable outcome was defined as favorable clinical response and documented or presumed microbial eradication (two negative follow-up blood cultures for bloodstream infections or a successful clinical response without follow-up cultures for other infections).
Favorable clinical response was defined as clinical resolution of signs and symptoms of infection and no need to change or add to antifungal therapy, or transition to oral antifungal to complete therapy.
|
Day 28 post-treatment
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of Participants With Unfavorable Outcome
Zeitfenster: Day 28 post-treatment
|
Unfavorable outcome was defined as the need to change to another antifungal agent because of lack of clinical response or death due to the antifungal infection or microbiologic persistence of the fungus or superinfection with a new Candida, Aspergillus or other fungal strain occurring at least 3 days and up to 14 days of anidulafungin therapy, or a lack of follow up data about clinical and microbiologic responses at the end of anidulafungin therapy.
|
Day 28 post-treatment
|
|
Percentage of Participants Who Died Due to All Causes
Zeitfenster: Baseline up to Day 28 post-treatment
|
Death due to all causes included death attributable to fungal infection, death unrelated to fungal infection and death due to multiple causes.
|
Baseline up to Day 28 post-treatment
|
|
Percentage of Participants With Death Attributable to Fungal Infection
Zeitfenster: Baseline up to Day 28 post-treatment
|
Baseline up to Day 28 post-treatment
|
|
|
Percentage of Participants With Death Unrelated to Fungal Infection
Zeitfenster: Baseline up to Day 28 post-treatment
|
Baseline up to Day 28 post-treatment
|
|
|
Percentage of Participants With Favorable Clinical Response
Zeitfenster: Day 28 post-treatment
|
Favorable clinical response was defined as clinical resolution of signs and symptoms of infection and no need to change or add to antifungal therapy, or transition to oral antifungal to complete therapy.
|
Day 28 post-treatment
|
|
Percentage of Participants With Lack of Clinical Response
Zeitfenster: Day 28 post-treatment
|
Favorable clinical response was defined as clinical resolution of signs and symptoms of infection and no need to change or add to antifungal therapy, or transition to oral antifungal to complete therapy.
|
Day 28 post-treatment
|
|
Percentage of Participants Requiring Change or Additional Antifungal Therapy
Zeitfenster: Baseline up to Day 28 post-treatment
|
Lower limit of confidence interval was reported as 0 if the same was calculated as less than 0 by standard calculations (outside the valid range of 0 to 100).
|
Baseline up to Day 28 post-treatment
|
|
Percentage of Participants With Oral Antifungal Started to Complete Therapy
Zeitfenster: Baseline up to Day 28 post-treatment
|
Baseline up to Day 28 post-treatment
|
|
|
Percentage of Participants With Documented Eradication of Infecting Species
Zeitfenster: Baseline
|
Documented microbial eradication was defined as 2 negative follow-up blood cultures for bloodstream infections.
|
Baseline
|
|
Percentage of Participants With Resolution of Signs of Infection According to Ultrasound Scan Results
Zeitfenster: Baseline up to Day 28 post-treatment
|
An ultrasound scan was performed and the resultant scan was reviewed for the presence of the infection as per investigator's discretion.
|
Baseline up to Day 28 post-treatment
|
|
Percentage of Participants With Resolution of Signs of Infection According to Computerized Tomography (CT) Scan Results
Zeitfenster: Baseline up to Day 28 post-treatment
|
A CT scan was performed and the resultant scan was reviewed for the presence of the infection as per investigator's discretion.
|
Baseline up to Day 28 post-treatment
|
|
Percentage of Participants With Abnormal Results for Liver Function at Initiation of Drug Therapy
Zeitfenster: Baseline
|
Percentage of participants with abnormal liver function results were based on 4 liver function variables- bilirubin, aspartate transaminase, alkaline phosphatase and gamma glutamyl transferase.
Normal reference ranges of these variables are: plasma bilirubin: 3-17 micromoles/L or 2.5-10 mg/L for adults; aspartate transaminase: 6-34 International Units/Liter (IU/L) for females and 8-40 IU/L for males; alkaline phosphatase: 5-38 IU/L for females and 10-50 IU/L for males; gamma glutamyl transferase: 7-32 IU/L for females and 11-50 IU/L for males.
Upper limit of confidence interval was reported as 100 if the same was calculated as greater than 100 by standard calculations (outside the valid range of 0 to 100).
|
Baseline
|
|
Percentage of Participants With Abnormal Results for Liver Function at End of Drug Therapy
Zeitfenster: Day 28 post-treatment
|
Percentage of participants with abnormal liver function results were based on 4 liver function variables- bilirubin, aspartate transaminase, alkaline phosphatase and gamma glutamyl transferase.
Normal reference ranges of these variables are: plasma bilirubin: 3-17 micromoles/L or 2.5-10 mg/L for adults; aspartate transaminase: 6-34 IU/L for females and 8-40 IU/L for males; alkaline phosphatase: 5-38 IU/L for females and 10-50 IU/L for males; gamma glutamyl transferase: 7-32 IU/L for females and 11-50 IU/L for males.
|
Day 28 post-treatment
|
|
Percentage of Participants With Liver Function Test Results at Least Twice the Baseline Value During Period of Drug Therapy
Zeitfenster: Baseline up to Day 28 post-treatment
|
Percentage of participants with liver function test results at least twice the baseline value during period of drug therapy was calculated for the liver function variables, bilirubin, aspartate transaminase, alkaline phosphatase and gamma glutamyl transferase.
|
Baseline up to Day 28 post-treatment
|
|
Percentage of Participants With Creatinine Clearance at Least Twice the Baseline Value During Period of Drug Therapy
Zeitfenster: Baseline up to Day 28 post-treatment
|
Baseline up to Day 28 post-treatment
|
|
|
Percentage of Participants Admitted to Liver Intensive Therapy Unit (LITU)
Zeitfenster: Baseline
|
Baseline
|
|
|
Duration of Stay at Liver Intensive Therapy Unit (LITU)
Zeitfenster: Baseline up to Day 28 post-treatment
|
Baseline up to Day 28 post-treatment
|
|
|
Percentage of Participants With Absolute Neutrophil Count Less Than 500 Per Cubic Millimeter (/mm^3) and Greater Than or Equal to 500 /mm^3
Zeitfenster: Baseline
|
Lower limit of confidence interval was reported as 0 if the same was calculated as less than 0 and upper limit of confidence interval was reported as 100 if the same was calculated as greater than 100, by standard calculations (outside the valid range of 0 to 100).
|
Baseline
|
|
Percentage of Participants With Concomitant Bacterial or Viral Infection
Zeitfenster: Baseline
|
Upper limit of confidence interval was reported as 100 if the same was calculated as greater than 100 by standard calculations (outside the valid range of 0 to 100).
|
Baseline
|
|
Percentage of Participants Prescribed With Systemic Antifungal Within 30 Days Before Study Start
Zeitfenster: Baseline
|
Lower limit of confidence interval was reported as 0 if the same was calculated as less than 0 by standard calculations (outside the valid range of 0 to 100).
|
Baseline
|
|
Dose Changes for Immunosuppressant Drugs
Zeitfenster: Baseline up to Day 28 post-treatment
|
Baseline up to Day 28 post-treatment
|
|
|
Percentage of Participants With Probable or Proven Fungal Infection at the Initiation of Drug Therapy
Zeitfenster: Baseline
|
Baseline
|
|
|
Percentage of Participants With Documented Body Temperature Above 38.0 Degree Celsius or Below 36.0 Degree Celsius Within 24 Hour Period Prior to Initiation of Drug Therapy
Zeitfenster: Baseline
|
Lower limit of confidence interval was reported as 0 if the same was calculated as less than 0 and upper limit of confidence interval was reported as 100 if the same was calculated as greater than 100, by standard calculations (outside the valid range of 0 to 100).
|
Baseline
|
|
Percentage of Participants With Systolic Blood Pressure More Than 2 Standard Deviations Below the Mean for Age Recorded Within 24 Hour Period Prior to Initiation of Drug Therapy
Zeitfenster: Baseline
|
Lower limit of confidence interval was reported as 0 if the same was calculated as less than 0 by standard calculations (outside the valid range of 0 to 100).
|
Baseline
|
|
Number of Participants With Infection Sites as Per Microbiological Analysis
Zeitfenster: Baseline
|
Infection sites included blood, chest, urinary tract, intra-abdominal, bile duct, liver, kidney, mouth and esophagus.
|
Baseline
|
|
Number of Participants With Infection Sites as Per Ultrasound Scan and Computerized Tomography (CT) Scan
Zeitfenster: Baseline
|
Baseline
|
|
|
Infecting Organisms by Species
Zeitfenster: Baseline up to Day 14 post-treatment
|
Baseline up to Day 14 post-treatment
|
|
|
Percentage of Participants With Prior Colonization With Candida by Species
Zeitfenster: Baseline
|
Lower limit of confidence interval was reported as 0 if the same was calculated as less than 0 by standard calculations (outside the valid range of 0 to 100).
|
Baseline
|
|
Percentage of Participants With Prior Colonization With Candida by Colonization Index
Zeitfenster: Baseline
|
Baseline
|
|
|
Percentage of Participants With Other Prior Fungal Infection by Species and Colonization Index
Zeitfenster: Baseline
|
Baseline
|
|
|
Number of Participants Who Received Water-based and Ethanol-based Formulation
Zeitfenster: Baseline
|
Baseline
|
|
|
Percentage of Participants Who Received Water-based and Ethanol-based Formulation
Zeitfenster: Baseline
|
Baseline
|
|
|
Percentage of Participants Who Received 200 mg Loading Dose
Zeitfenster: Day 1
|
Day 1
|
|
|
Percentage of Participants Who Received 100 mg Dose on Day 2
Zeitfenster: Day 2
|
Day 2
|
|
|
Percentage of Participants Who Received 200 mg Dose on Day 1 and 100 mg for All Subsequent Doses
Zeitfenster: Baseline up to Day 28 post-treatment
|
Baseline up to Day 28 post-treatment
|
|
|
Number of Participants With Other Dosing Patterns
Zeitfenster: Baseline up to Day 28 post-treatment
|
The other dosing patterns for anidulafungin included any dosing pattern different from 200 mg loading dose on Day 1 followed by 100 mg doses subsequently starting from Day 2.
|
Baseline up to Day 28 post-treatment
|
|
Duration of Anidulafungin Therapy
Zeitfenster: Baseline
|
Baseline
|
|
|
Number of Serious Adverse Events (SAEs)
Zeitfenster: Baseline up to Day 28 post-treatment
|
Any untoward medical occurrence in a participant who received study treatment was considered an adverse event (AE) without regard to possibility of causal relationship.
An AE resulting in any of the following outcomes, or deemed to be significant for any other reason, was considered to be a SAE: death; initial or prolonged inpatient hospitalization; a life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
|
Baseline up to Day 28 post-treatment
|
|
Percentage of Participants With One or More Drug-related Serious Adverse Events (SAEs)
Zeitfenster: Baseline up to Day 28 post-treatment
|
Baseline up to Day 28 post-treatment
|
|
|
Number of Participants With Different Types of Drug-related Serious Adverse Events
Zeitfenster: Baseline up to Day 28 post-treatment
|
Baseline up to Day 28 post-treatment
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Publikationen und hilfreiche Links
Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn
1. Februar 2011
Primärer Abschluss (Tatsächlich)
1. Mai 2011
Studienabschluss (Tatsächlich)
1. Mai 2011
Studienanmeldedaten
Zuerst eingereicht
13. September 2010
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
13. September 2010
Zuerst gepostet (Schätzen)
15. September 2010
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
16. April 2014
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
25. März 2014
Zuletzt verifiziert
1. März 2014
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- A8851028
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .